TITLE

Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation

AUTHOR(S)
Taylor, I K
PUB. DATE
September 1995
SOURCE
Thorax;Sep1995, Vol. 50 Issue 9, p1005
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66026077

 

Related Articles

  • Leukotriene Receptors and Aspirin Sensitivity. Arm, Jonathan P.; Austen, K. Frank // New England Journal of Medicine;11/7/2002, Vol. 347 Issue 19, p1524 

    Editorial. Argues that a study by Sousa et al. provides insight into the abnormalities of cysteinyl luekotiene pathways in aspirin-sensitive asthma. Increased basal biosynthesis of the cysteinyl leukotrienes in aspirin-sensitive asthma; How disregulation of the receptors for the cysteinyl...

  • Leukotriene modifiers in the treatment of asthma. Sampson, Anthony; Holgate, Stephen // BMJ: British Medical Journal (International Edition);04/25/98, Vol. 316 Issue 7140, p1257 

    Editorial. Looks at the treatment of asthma with the use of leukotriene modifiers. Reference to leukotriene synthesis inhibitors and cysteinyl leukotriene receptor antagonists, which are the two types of leukotriene modifiers; Detailed information on the two leukotriene modifiers; Relation to...

  • Inhibition of Leukotriene Biosynthesis by Secondary Plant Metabolites. Adams, Michael; Bauer, Rudolf // Current Organic Chemistry;May2008, Vol. 12 Issue 8, p602 

    Leukotrienes (LTs) are a group of biologically highly potent mediators of inflammation, synthesised in the first metabolic step by 5-lipoxygenase from 20 carbon fatty acids, predominantly arachidonic acid. They include the cysteinyl leukotrienes LTC4, LTD4, LTE4, which cause bronchoconstriction,...

  • Defining the role of antileukotriene agents in the management of asthma. Johnson, Margaret M. // Formulary;Jan2000, Vol. 35 Issue 1, p38 

    The newest class of asthma medications to be marketed in the United States are the antileukotriene agents (ALAs). They include one 5-lipoxygenase inhibitor, zileuton, and two leukotriene receptor antagonists, zafirlukast and montelukast. By inhibiting the formation of cysteinyl leukotrienes or...

  • Citations and Clinicians' Notes: Basic Mechanisms.  // Current Medical Literature: Allergy;2003, Vol. 11 Issue 3, p48 

    Focuses on the expression of the cysteinyl leukotrienes in cultured human bronchial smooth muscle cells exposed to cytokines. Pathogenesis of asthma symptoms and airway remodeling; Enhancement of cellular proliferation; Response of human bronchial smooth muscle cells to the leukotrienes.

  • The Potential Role of Tocopherol in Asthma and Allergies: Modification of the Leukotriene Pathway. Centanni, S.; Santus, P.; Dimarco, F.; Fumagalli, F.; Zarini, S.; Sala, A. // BioDrugs;2001, Vol. 15 Issue 2, p81 

    Metabolism of arachidonic acid via the 5-lipoxygenase (5-LO) pathway leads to the formation of hydroperoxyeicosatetraenoic acids (HPETEs) and leukotriene (LT) A. This unstable allylic epoxide can be further converted by secondary enzymes into LTB and cysteinyl LTs. LTs represent a family of...

  • Update on the use of montelukast in pediatric asthma. Capristo, Carlo; Rigotti, Erika; Boner, Attilio L. // Allergy & Asthma Proceedings;Jul/Aug2006, Vol. 27 Issue 4, p312 

    Cysteinyl leukotrienes are inflammatory bioactive lipids produced by various cells. They are present in increased amounts in airway secretions of all different asthma phenotypes and can induce all the inflammatory changes observed in the airways of asthmatic patients. For this reason, an attempt...

  • Leukotrienes, Antileukotrienes and Asthma. Montuschi, Paolo // Mini Reviews in Medicinal Chemistry;Jun2008, Vol. 8 Issue 7, p647 

    Leukotrienes (LTs), including LTB4 and cysteinyl-LTs (CysLTs) (LTC4, LTD4, and LTE4), are potent inflammatory lipid mediators which are derived from 5--lipoxygenase activity. CysLTs, which stimulate CysLT1 and CysLT2 receptor subtypes, are functionally involved in the pathophysiology of asthma....

  • A risk-benefit assessment of antileukotrienes in asthma. Smith, L.J. // Drug Safety;Sep1998, Vol. 19 Issue 3, p205 

    The antileukotriene drugs are the first new therapeutic agents approved for the treatment of asthma in more than 20 years. The currently available compounds are orally active and either prevent the cysteinyl leukotrienes from binding to and activating the cysLT-1 receptor in the lung...

  • Cysteinyl Leukotriene Receptor Antagonists and Thromboxane Synthase Inhibitors: New Targets to Treat Asthma. Lima, L�dia M.; Fraga, Carlos Alberto M.; Barreiro, Eliezer J. // Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy A;Mar2004, Vol. 3 Issue 1, p9 

    Cysteinyl leukotrienes (LTC 4 , LTD4 and LTE4 ) and thromboxane A2 are important metabolites of arachidonic acid cascate involved in a variety of cellular functions and diseases. These eicosanoids have been implicated as key mediators in the development and progression of bronchial asthma....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics